镭-223用于治疗激素难治性前列腺癌伴骨转移的男性患者。 - Suppr

Suppr

超能文献

Radium-223 for men with hormone-refractory prostate cancer and bone metastases.

作者信息

Shelley Mike D, Mason Malcolm D

出版信息

Lancet Oncol. 2007 Jul;8(7):564-5. doi: 10.1016/S1470-2045(07)70180-8.

DOI:10.1016/S1470-2045(07)70180-8

PMID:17613416

Abstract

摘要

相似文献

Radium-223 for men with hormone-refractory prostate cancer and bone metastases.

Lancet Oncol. 2007 Jul;8(7):564-5. doi: 10.1016/S1470-2045(07)70180-8.

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

Lancet Oncol. 2007 Jul;8(7):587-94. doi: 10.1016/S1470-2045(07)70147-X.

Clinical benefits of alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review.

BMJ Case Rep. 2012 Nov 1;2012:bcr2012006540. doi: 10.1136/bcr-2012-006540.

Prognostic factors in metastatic prostate cancer.

Urol Oncol. 2011 Mar-Apr;29(2):162-5. doi: 10.1016/j.urolonc.2009.03.013. Epub 2009 May 17.

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.

Cancer. 2007 Dec 15;110(12):2709-15. doi: 10.1002/cncr.23111.

Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223.

Scand J Urol. 2015 Jun;49(3):211-7. doi: 10.3109/21681805.2014.982169. Epub 2014 Dec 17.

Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects.

Oncology (Williston Park). 2015 Jul;29(7):483-8.

Radium-223 vs EBRT for multiple painful bone metastases: the data favor radium-223.

Oncology (Williston Park). 2014 Apr;28(4):296, 298.

Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.

Eur Urol. 2007 Nov;52(5):1381-7. doi: 10.1016/j.eururo.2007.02.033. Epub 2007 Feb 20.

A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

Eur Urol. 2013 Feb;63(2):189-97. doi: 10.1016/j.eururo.2012.09.008. Epub 2012 Sep 13.

引用本文的文献

The Na+/I- symporter (NIS): mechanism and medical impact.

Endocr Rev. 2014 Feb;35(1):106-49. doi: 10.1210/er.2012-1036. Epub 2013 Dec 4.

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer.

Cancer Discov. 2013 Aug;3(8):849-61. doi: 10.1158/2159-8290.CD-12-0460. Epub 2013 Jun 28.

Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.

The biology of the sodium iodide symporter and its potential for targeted gene delivery.

Curr Cancer Drug Targets. 2010 Mar;10(2):242-67. doi: 10.2174/156800910791054194.

Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000.

[Pain palliation using unsealed radionuclides].

Schmerz. 2008 Dec;22(6):699-705; quiz 706. doi: 10.1007/s00482-008-0712-2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验